SEC Form 4 · accession 0000950142-15-000939
Esperion Therapeutics, Inc. · ESPR
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Dov A Goldstein M.D.
Director
Period of report
Apr 28, 2015
Accepted (ET)
Apr 30, 2015 · 4:26 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001434868
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Apr 28, 2015 | J | 199,991 | $0.00 | D | 1,637,125 | I | By Aisling Capital II, LP |
| Common Stock | holding | — | — | — | 9 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On April 28, 2015, Aisling Capital II, LP ("Aisling") distributed 200,000 shares of Common Stock (the "Shares") of Esperion Therapeutics, Inc. (the "Issuer") to its general and limited partners on a pro-rata basis. Of the 200,000 Shares distributed by Aisling, Aisling Capital Partners, LP ("Aisling GP") received its pro-rata interest of 2,000 Shares, which it immediately distributed to its general and limited partners, including Dr. Goldstein, who received (and now directly holds) his pro-rata interest, consisting of 9 Shares.
- F2The reportable securities are owned directly by Aisling, and held indirectly by Aisling GP, as general partner of Aisling, and Aisling Capital Partners, LLC ("Aisling Partners"), as general partner of Aisling GP. Dr. Goldstein is a member of the investment committee of Aisling. Dr. Goldstein disclaims beneficial ownership of these securities and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose, except to the extent of his pecuniary interest therein.